Article Dans Une Revue Intensive Care Medicine Année : 2021

Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis

Dipayan Chaudhuri
  • Fonction : Auteur
Kiyoka Sasaki
  • Fonction : Auteur
Aram Karkar
  • Fonction : Auteur
Sameer Sharif
  • Fonction : Auteur
Kimberley A. Lewis
  • Fonction : Auteur
Manoj J. Mammen
Paul Elías Alexander
  • Fonction : Auteur
Zhikang Ye
  • Fonction : Auteur
Luis Enrique Colunga Lozano
  • Fonction : Auteur
Marie Warrer Munch
  • Fonction : Auteur
Anders Perner
  • Fonction : Auteur
Bin Du
Lawrence C.E. Mbuagbaw
Waleed Alhazzani
  • Fonction : Auteur
Stephen Mccarthy Pastores
John C. Marshall
  • Fonction : Auteur
François C. Lamontagne
  • Fonction : Auteur
Gianfranco Umberto Meduri
  • Fonction : Auteur
Bram Rochwerg
  • Fonction : Auteur correspondant
  • PersonId : 1101701

Connectez-vous pour contacter l'auteur

Résumé

Purpose: Corticosteroids are now recommended for patients with severe COVID-19 including those with COVID-related ARDS. This has generated renewed interest regarding whether corticosteroids should be used in non-COVID ARDS as well. The objective of this study was to summarize all RCTs examining the use of corticosteroids in ARDS. Methods: The protocol of this study was pre-registered on PROSPERO (CRD42020200659). We searched online databases including MEDLINE, EMBASE, CDC library of COVID research, CINAHL, and COCHRANE. We included RCTs that compared the effect of corticosteroids to placebo or usual care in adult patients with ARDS, including patients with COVID-19. Three reviewers abstracted data independently and in duplicate using a pre-specified standardized form. We assessed individual study risk of bias using the revised Cochrane ROB-2 tool and rated certainty in outcomes using GRADE methodology. We pooled data using a random effects model. The main outcome for this review was 28-day-mortality. Results: We included 18 RCTs enrolling 2826 patients. The use of corticosteroids probably reduced mortality in patients with ARDS of any etiology (2740 patients in 16 trials, RR 0.82, 95% CI 0.72–0.95, ARR 8.0%, 95% CI 2.2–12.5%, moderate certainty). Patients who received a longer course of corticosteroids (over 7 days) had higher rates of survival compared to a shorter course. Conclusion: The use of corticosteroids probably reduces mortality in patients with ARDS. This effect was consistent between patients with COVID-19 and non-COVID-19 ARDS, corticosteroid types, and dosage.

Dates et versions

hal-03256433 , version 1 (10-06-2021)

Identifiants

Citer

Dipayan Chaudhuri, Kiyoka Sasaki, Aram Karkar, Sameer Sharif, Kimberley A. Lewis, et al.. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine, 2021, 47 (5), pp.521-537. ⟨10.1007/s00134-021-06394-2⟩. ⟨hal-03256433⟩
104 Consultations
0 Téléchargements

Altmetric

Partager

  • More